{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"MiST","nct_id":"NCT03654833","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mist-nct03654833. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MiST","arms":[{"description":"BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.","label":"MiST1 Rucaparib","type":"EXPERIMENTAL"},{"description":"p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.","label":"MiST2 Abemaciclib","type":"EXPERIMENTAL"},{"description":"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:\n\nBemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days.","label":"MiST3 Pembrolizumab & Bemcentinib","type":"EXPERIMENTAL"},{"description":"PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.","label":"MiST4 Atezolizumab & Bevacizumab","type":"EXPERIMENTAL"},{"description":"Platinum sensitive mesothelioma: Niraparib 200-300mg daily every 21 days; Dostarlimab 500mg on day 1 of each 21 day cycle for 4 cycles, then 1000mg on day 1 of each 42 day cycle.","label":"MiST 5 Dostarlimab and Niraparib","type":"EXPERIMENTAL"}],"collaborators":["British Lung Foundation","Clovis Oncology, Inc.","Eli Lilly and Company","Merck Sharp & Dohme LLC","BerGenBio ASA","Roche Pharma AG","University Hospitals, Leicester","The Christie NHS Foundation Trust","GlaxoSmithKline"],"completion_date":{"date":"2024-03-15","type":"ACTUAL"},"conditions":["Mesothelioma, Malignant"],"enrollment":{"count":186,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Rucaparib","otherNames":["CO-338"],"type":"DRUG"},{"name":"Abemaciclib","otherNames":["LY2835219"],"type":"DRUG"},{"name":"pembrolizumab & bemcentinib","otherNames":["Keytruda; BGB324"],"type":"DRUG"},{"name":"Atezolizumab & Bevacizumab","otherNames":["MPDL3280A; Avastin"],"type":"DRUG"},{"name":"Dostarlimab and Niraparib","otherNames":["Zejula"],"type":"DRUG"}],"last_update":"2026-08-17","lead_sponsor":"University of Leicester","official_title":"Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-02-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.","timeFrame":"12 weeks"}],"references":[{"citation":"Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, Nusrat N, Scotland M, Bhundia V, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Bajaj A, Richards C, Wells-Jordan P, Thomas A; MiST2 study group. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022 Mar;23(3):374-381. doi: 10.1016/S1470-2045(22)00062-6. Epub 2022 Feb 11.","pmid":"35157829","type":"DERIVED"},{"citation":"Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Nicholson A, Richards C, Wells-Jordan P, Murphy GJ, Thomas A; MiST1 study group. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021 Jun;9(6):593-600. doi: 10.1016/S2213-2600(20)30390-8. Epub 2021 Jan 27.","pmid":"33515503","type":"DERIVED"}],"start_date":{"date":"2019-01-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma","url":"https://clinicaltrials.gov/study/NCT03654833"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mist-nct03654833"}